Losartan with hydrochlorothiazide
Brand names: Cozaar-Comp
This is a fixed-dose combination of losartan, an angiotensin-II receptor blocker (ARB), with the thiazide diuretic hydrochlorothiazide, used to treat essential hypertension when blood pressure is not adequately controlled by either component alone.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Losartan blocks the angiotensin-II type 1 receptor to cause vasodilatation and reduce aldosterone-mediated sodium retention, while hydrochlorothiazide enhances renal sodium and water excretion, giving additive blood-pressure lowering.
Prescribing in practice
- The combination is contraindicated in pregnancy because the ARB component can cause serious foetal harm and must be discontinued as soon as pregnancy is detected.
- Avoid dual blockade of the renin-angiotensin system, and take care with potassium supplements or potassium-sparing diuretics because the combined potassium effect is unpredictable.
- Hydrochlorothiazide can provoke hyponatraemia, hypokalaemia, gout and photosensitivity, and is associated with a small increased risk of non-melanoma skin cancer.
Monitoring
Monitor blood pressure, renal function and serum electrolytes (sodium and potassium) before and during treatment, especially after dose adjustment or intercurrent illness.
Counselling the patient
- Do not take this medicine if you are or might become pregnant, and tell your doctor straight away if you conceive.
- Protect your skin from strong sunlight while on the diuretic component.
- Report dizziness, muscle cramps or unusual thirst, which can indicate a salt or water imbalance.
Evidence & guidelines
Combining an ARB with a thiazide diuretic for blood pressure uncontrolled on monotherapy aligns with NICE hypertension guidance and established trial evidence for the class.
Reference: NICE NG136; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines